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Chinese hamster ovary cells are the main mammalian cell expression system currently used 
for the production of recombinant protein biopharmaceuticals. One of the key processes 
determining the achievable biomass of cells in the bioreactor and the yield and quality of 
recombinant protein from such systems is mRNA translation. Translation is the process by 
which ribosomes and associated cellular machinery decode an mRNA to produce a 
polypeptide. In recent years the roles of different classes of non-coding RNAs in controlling 
global and transcript specific mRNA translation has also come to light. Here we review 
approaches to engineer the translational machinery and non-coding RNAs, particularly 
long non-coding RNAs and tRNAs in CHO cells and then outline the challenges and potential 
of such approaches to revolutionize the yields and quality of recombinant protein from 




For the production of biopharmaceuticals, Chinese hamster ovary (CHO) cells are the most 
widely used mammalian cell expression system, able to produce secretory yields of 
monoclonal antibody in fed-batch culture in excess of 5 g/L [1]. The secretory yield from 
such an expression system is governed by the number of cells in the bioreactor across the 
culture (the integral of viable cell concentration or IVC) and the average amount of material 
expressed by each cell, usually referred to as the cell specific productivity (qP) and 
expressed as pg of protein/per cell/per day [2]. mRNA translation is a key cellular process 
that is involve in determining global and protein specific synthesis, and hence control of 
the abundance of proteins that constitute the cellular machinery, cell growth, division and 
the IVC of culture. Likewise, mRNA translation plays a key role in determining the qP of a 
given cell line and hence is a key regulatory process impacting on the yields and quality of 
recombinant protein from CHO cells [3].  
mRNA translation is the process by which the ribosome and associated cellular machinery 
decodes a target mRNA to yield a polypeptide. Translation is a key step in the gene 
expression pathway and is the predominant process by which protein cellular abundance 
is controlled [4]. Over the last few decades it has been established that the control in 
mammalian cells of mRNA translation, and hence protein synthesis, is not only determined 
by the translational machinery, modulation of the activity of various translation factors by 
phosphorylation, and the abundance, availability and makeup of a given mRNA, but also 
by availability, abundance and activity of non-coding RNAs [5]. Non-coding RNAs are 
generally described as either long non-coding RNAs of >200 nucleotides in length or small 
non-coding RNAs <200 nucleotides and includes microRNAs (also referred to as miRs) and 
tRNAs. The discovery of the mechanism(s) by which non-coding RNAs exert an influence 
on gene expression has opened up new opportunities for the engineering of cells to 
manipulate cell processes that underpin cell growth and recombinant protein production 
and quality. Further, manipulation of such non-coding RNAs offers the advantage of not 
placing an additional translational burden on the cell that over-expression of coding 
mRNAs does. Here we briefly review our understanding of the control of mRNA translation 
in CHO cells, describe approaches and outcomes to engineer the translational machinery 
and non-coding RNAs in CHO cells, and discuss current and future cell engineering 
opportunities and challenges such approaches present (Summarized in Table 1).  
THE TRANSLATIONAL MACHINERY, mRNA ANALYSIS AND MANIPULATION 
As mRNA translation is a key process in defining cell growth, biomass accumulation and 
recombinant protein yields and quality from cultured CHO cells [3,6], the translational 
machinery and the abundance and availability of global and recombinant mRNAs between 
cell lines and process conditions has been investigated using a variety of approaches. For 
example, the phosphorylation of the translation initiation factor eIF2 and attenuation of 
global protein synthesis during recombinant protein production in CHO cells is known to 
occur [7]. Culture temperature has been shown to impact mRNA translation and the quality 
of recombinant product produced [8] and the PERK-eIF2 pathway was reported to impact 
upon the aggregation of a recombinant TNFR-Fc fusion protein [9]. Indeed the activity and 
availability of translation factors has been shown to change during culture and under 
different culture conditions, where for example under reduced temperature translation 
elongation factor 2 (eEF2) becomes phosphorylated and a reprogramming of translation 
occurs that means transcripts with particular codon usage can escape the general global 
attenuation of translation under such conditions and the translation of these transcripts is 
actually enhanced [10].  
High producing antibody cell lines have been shown to maintain translation initiation 
factors at levels that allow such cells to maintain enhanced recombinant protein synthesis 
above that of lower producing cells [3]. With regard to monoclonal antibody synthesis in 
CHO and other cells, investigations have shown that recombinant antibody production is 
limited by translational efficiency [3,11-13]. Manipulation of the cellular translational 
machinery is however, not straightforward. One global regulator of ribosome biogenesis 
and translation is mTORC1, which coordinates cellular responses to signaling pathways 
involved in sensing growth factors, nutrient availability, intracellular energy status and 
other perceived cell stresses and modulates translation and ribosome biogenesis in 
response [14]. In particular, mTORC1 can influence translation initiation via 
phosphorylation of eukaryotic initiation factor 4E binding protein (4E-BP1), which when 
phosphorylated at multiple sites promotes dissociation of 4E-BP1 from the initiation factor 
eIF4E. Increased phosphorylation of 4E-BP1 has been correlated with increased interferon-
 production [15] whilst the stoichiometry of 4E-BP1 to eIF4E is reported to relate to 
recombinant antibody productivity [16]. Exogenous mTOR expression has also been shown 
to enhance recombinant protein expression in CHO cells by improving cell viability, growth, 
proliferation and cell specific productivity [17].  
One approach applied to investigate mRNA amounts, and hence determine gene 
expression profiles of high producing or fast growing recombinant cell lines is 
transcriptomics. A general assumption of most such studies is that the amount of mRNA 
present at a given timepoint reflects the ‘state’ or ‘need’ of a cell with regard to the 
proteins that these mRNAs encode for. As such, transcriptomic profiling has been applied 
to identify mRNAs whose abundance correlates with cell growth and recombinant protein 
productivity and quality with a view to using the identification of such targets to engineer 
the cell for improved performance. Many of these initial studies were hampered by the 
lack of the CHO genome and appropriate arrays, however the elucidation of the genome 
[18,19] and advent of RNA-Seq has made it possible to undertake such studies with a higher 
degree of precision. Despite this, there has been little consensus across transcriptomic 
studies to date with regard to those mRNAs that correlate with cell growth and 
recombinant protein productivity [20]. Further, previous correlation analysis has shown 
that transcript amounts and translation efficiency are uncoupled for around 95% of 
investigated genes [21], providing strong evidence that global and mRNA specific 
translational control needs to be understood and determined to evaluate the impact of 
mRNAs on phenotype rather than simple mRNA abundance itself.  
In order to address this issue, investigators have begun to apply ribosome footprint 
profiling or RiboSeq analysis to unravel the fine detail of translational control in CHO cells 
[22]. This powerful approach allows genome wide, but also transcript specific, detail on 
initiation and elongation stages of mRNA translation to be studied and identification of 
those mRNAs that are being translated at any given time (as opposed to just their 
abundance), the efficiency of mRNA translation and how this changes during a process or 
between cell lines to identify targets for cell line engineering [22]. Indeed, any given mRNA 
in the cell may be translated by one or multiple ribosomes (so call polysomes) at any one 
time [23]. In some cases the number of ribosomes per transcript has been used to estimate 
translational efficiency of a transcript assuming that more ribosomes on a transcript 
indicates greater translational efficiency [24], but this does not account for elongation 
speed that RiboSeq analysis can. RNA-Seq approaches can also potentially be used to 
investigate translational activity at the single cell level. The application of such approaches 
is certain to provide a more detailed understanding of mRNA translation and its control in 
recombinant protein producing CHO cells, at the population and single cell level and at a 
global and transcript specific level, revealing new engineering approaches by which 
translation can be modulated to enhance protein production. 
microRNAs and siRNAs 
mRNA translation can also be tuned by non-coding RNAs. One such class of non-coding 
RNA that has been applied to reprogramming translation in CHO cells is that of microRNAs 
(also known as miRs or miRNAs). The potential application of microRNAs to CHO cell 
engineering has recently been reviewed elsewhere [25]. These RNAs are transcribed as 
long primary transcripts but then processed to yield small (20-23 nucleotide) non-coding 
RNAs and were first described in C. elegans. MicroRNAs tend to act as repressors of 
translation of target mRNAs by interacting with the 3’untranslated regions (3’UTRs) of such 
mRNAs. A given microRNA can in theory target multiple mRNAs via base pairing and hence 
modulate multiple mRNAs and pathways without placing an additional translational 
burden on the cell [25].  
Early microRNA studies were limited by the lack of available Chinese hamster sequence 
annotation of microRNA primary transcripts, and hence chimeric microRNAs that 
contained the mature miR sequence but flanking sequences in the primary transcript from 
other species were used. Subsequent studies showed that endogenous CHO microRNA 
flanking sequences gave rise to higher expression when over-expressing microRNAs [26]. 
Recent engineering approaches harnessing microRNAs include studies that look to enhance 
the ability of CHO cells to produce so called ‘difficult to express proteins’. For example, one 
such study showed that a CHO cell line constitutively over-expressing miR-557 and a 
difficult to express antibody produced twice the antibody yield of cells engineered to 
express a negative control microRNA [27]. A further study reported that both transient and 
stable miR-143 over-expression resulted in enhanced difficult to express protein 
production and targeted MAPK7 in CHO [28]. The natural repertoire of microRNAs has also 
been harnessed to repress expression of the DHFR selection marker during cell line 
construction and allow the generation of higher producing cell pools [29]. Others have 
shown that microRNA fingerprints or signatures can be correlated with growth rate across 
a number of different CHO cell lines [30]. 
However, although microRNA engineering appears an attractive approach by which to tune 
translation of multiple mRNAs and translation of specific targets, the potential large 
number of predicted targets of any given microRNA means that the outcome of such 
engineering approaches can be difficult to predict as is identifying which targets a given 
microRNA interacts with. Barron and colleagues have described a system termed ‘miR-
CATCH’ that allows the investigator to identify those microRNAs that interact with a given 
target and thus validate these for potential cell engineering approaches [31•]. The authors 
had identified that the overexpression of the X-linked inhibitor of apoptosis (XIAP) 
enhanced CHO cell productivity, growth and culture longevity. To avoid overexpressing this 
gene and placing an additional translational burden on the cell, microRNA regulators of 
XIAP were identified using a biotin-labelled antisense DNA for XIAP resulting in the capture 
of interacting microRNAs. Inhibition of two of these microRNAs resulted in increased XIAP 
protein expression, validating the microRNA catch approach and the utility of this for 
identifying cell engineering targets.  
The use of small interfering RNAs (siRNAs) has also proved to be an effective strategy for 
CHO cell line engineering to selectively knockdown expression of target genes detrimental 
to cell growth or productivity. The advantage of knockdown, as opposed to knockout 
strategies, is that essential genes can be reduced in their expression and the impact on cell 
phenotype assessed when knockout proves fatal. One successful application of siRNA 
engineering has been the inhibition of lactate dehydrogenase-A (LDH-A) on its own [32], or 
in combination with pyruvate dehydrogenase kinases (PDHKs) [33] to significantly reduce 
lactate accumulation in cultured CHO cells without negatively impacting cell growth and 
enhancing cell specific productivity. A further group undertook ribosomal profiling in CHO 
cells and identified the resistance marker NeoR as being highly transcribed and translated, 
and as expression of this exogenous gene in CHO cells is not required, used siRNA 
knockdown to reduce its expression with a resultant improvement in production and 
growth of the host observed [34]. Finally, an siRNA approach was used to knockdown the 
expression of the endoplasmic reticulum localized proteins ceramide synthase 2 (CerS2) 
and Rab1 GAP Tbc domain family member 20 (Tbc1D20) in CHO IgG producing cells with a 
subsequent observed increase in recombinant protein specific productivity and enhanced 
cell growth [35]. 
LONG NON-CODING RNAs (lncRNAs) AND THEIR MANIPULATION 
Recent genome wide analysis in mammalian cells estimates that 75% of the transcriptome is 
composed of non-coding sequences [36] and led to the identification of a heterogeneous class 
of transcripts known as Long non-coding RNAs (lncRNAs) [37]. LncRNAs are defined as 
transcripts longer than 200 nucleotides that lack a significant open reading frame (ORF) and 
are usually transcribed by RNA polymerase II and spliced, with or without, 3’ polyadenylation 
[38]. These molecules are emerging as key regulators in various biological processes both in 
the nucleus and the cytoplasm [39], including epigenetic regulation, transcriptional control, 
splicing events, and mRNA translation. While most of our current understanding into lncRNAs 
and the underlying mechanism(s) by which they elicit their responses has come from studies 
relating to disease and developmental studies, their potential as targets for cell engineering 
in mammalian cell factories remains largely unexplored.  
The first analysis of the non-coding transcriptome in CHO cells under batch and fed-batch 
conditions has recently been published, unveiling a number of differentially regulated 
lncRNAs depending on feed and culture time which could be targets for cell engineering [40•]. 
One of the main challenges in identifying lncRNAs is the low sequence conservation between 
species. This, coupled with incomplete genome sequences and partial annotations of coding 
and non-coding genes of most vertebrates including Chinese hamster, have impaired an 
effective lncRNAs annotation outside from model organisms (Figure 1).  
A recent study compared lncRNAs among 16 vertebrates and the echinoid sea urchin finding 
thousands of human lincRNAs homologs with conserved genomic position sharing 5’-biased 
patches of sequence nested in rewired exonic architectures [41]. The FANTOM consortium 
applied a cap analysis of gene expression (CAGE) to data obtaining more than 27,919 human 
lncRNA genes with high-confidence 5′ ends and expression profiles across 1,829 samples from 
the major human primary cell types and tissues [42]. Through the incorporation of 
conservation and expression data, the consortium was able to identify 19,175 potentially 
functional lncRNAs in the human genome. Due to the tissue-specificity of lncRNAs, comparing 
the expression among several cell types has led to a more robust identification of functional 
targets. By modelling their effects on the activity of transcription factors, RNA-binding 
proteins, and microRNAs in 5,185 TCGA tumors and 1,019 ENCODE assays, it was possible to 
identify potential lncRNAs involved in dysregulated cancer pathways. This approach indicated 
OIP5-AS1, TUG1, NEAT1, MEG3, and TSIX, as synergic lncRNAs leading to dysregulated cancer 
pathways in multiple tumor contexts [43]. A similar effort using nascent RNA capture 
sequencing identified 1145 temporally expressed S-phase-enriched lncRNAs across TCGA 
data sets in several cancer models showing effects on pathways including FGF/FGFR and its 
downstream PI3K/AKT and MAPK pathways [44].  
The NEAT1 lncRNA is a central component of paraspeckles, nuclear bodies that regulate 
multiple aspects of gene expression, promoting their formation through ATR signaling in 
response to replication stress and p53 activation [45]. The RNA-binding NONO–PSF 
heterodimer binds a large number of expressed pri-miRNAs in the paraspeckles to promote 
processing by the Drosha–DGCR8 Microprocessor. NEAT1 thus regulates efficient processing 
of potentially an entire class of small non-coding RNAs in the nucleus by interaction with the 
NONO–PSF heterodimer as well as other ribosome binding proteins (RBPs) [46]. 
The relationship between lncRNAs and the translational machinery was further elucidated 
with the discovery of a long nucleolus-specific lncRNA (LoNA) [47•]. LoNA is expressed at high 
levels at resting state suppressing rRNAs transcription in the nucleoli through the combined 
effects of its 5′ portion, which binds and sequesters nucleolin, and its snoRNA like 3′ end, 
which recruits and diminishes fibrillarin activity to reduce rRNA methylation. When the cell 
needs to sustain an elevated translational load, LoNA expression decreases leading to 
elevated rRNA and ribosome levels, an increased proportion of polysomes, mRNA polysome 
loading, and eventually protein synthesis. 
The first successful engineering of lncRNAs for enhanced recombinant protein production 
involved manipulation of SINEUPs, natural and synthetic antisense lncRNAs that can activate 
translation in a gene-specific manner using an inverted SINEB2 sequence [48]. A Binding 
Domain (BD) located towards the 5’ region of the SINEUP overlaps a target mRNA of choice 
conferring specificity, while an inverted SINEB2 element defined as the Effector Domain (ED) 
provides the translation activation function [49]. Synthetic SINEUPs have been used to 
increase translation and secretion of recombinant proteins in a range of mammalian cell lines, 
including CHO [50••] and HEK293 [51•]. As further studies define those lncRNAs present in 
CHO cells and how these influence cell growth, fate and recombinant protein production, 
engineering of these non-coding RNAs is sure to offer potential to further tune and enhance 
mRNA specific and global mRNA translational efficiency. 
tRNAs AND TRANSLATION 
The use of specific codons with high gene copy number and high codon bias coupled with the 
modulation of intracellular tRNA concentration has been shown to improve protein 
production in CHO cells [52]. However, despite translational efficiency often being 
considered the mere result of codon optimization based on the correlation between codon 
bias and tRNA gene copy numbers (Figure 2), recent evidence suggests a considerably more 
intricate picture where ribosome collisions, co-translational folding, mRNA stability, 
composition, charge status and post-transcriptional modifications of the tRNA pool all 
contribute to finely tune protein production in response to the environment [53]. 
Controlling the translational capacity of an expression system through the use of 
alternative codon combinations modulates ribosome decoding speed, impacting protein 
quality as well as final yield [54]. The use of suboptimal codons has been reported to slow 
translation at key structural motifs in order to facilitate correct co‑translational 
polypeptide folding and signal recognition particle (SRP) recognition, which assists in 
protein translocation across membranes [55]. Thus, although recombinant genes are often 
‘codon optimized’, we do not currently have all the information required around codon 
usage, context, tRNA abundance, modifications and charging to fully harness codon usage 
in recombinant sequences or to engineer tRNA abundance.  
Codon bias has been referred to as a secondary genetic code that impacts on the fidelity 
of translation, efficiency of translation, polypeptide/protein folding and mRNA 
stability/half-life [56]. The cell utilizes such codon effects to tailor the proteome and allow 
reprogramming, such as under cold stress whereby reprogramming and synthesis of 
specific proteins is enhanced through codon bias [10]. Codon bias or optimization is also 
linked to tuning mRNA stability and stable mRNAs are found to be enriched in codons that 
are considered optimal whilst also impacting on ribosome translocation [57]. Specific 
combinations of adjacent codons in yeast and mammalian cells can have an effect on 
translation efficiency resulting in reduced expression, proving how the focus must be on 
global translation efficiency and codon context as opposed to single codons optimality [58•-
60]. On top of this, mRNA secondary structure combined with tRNA abundance modulate 
translational elongation speed among different regions of the same transcript to avoid 
excessively slow or fast ribosome movement [61]. As such, there remains enormous potential 
to enhance recombinant protein yields from further manipulation of codon usage. 
In order to further enhance recombinant protein yields by manipulation of codon usage it is 
necessary to further understand the abundance and modifications of tRNAs and the role 
these play in their activity. Determination of tRNA copy numbers can now be undertaken 
using RNA-Seq approaches. tRNA secondary structure and nucleotide modifications, mainly 
methylations, impair the efficiency of standard sequencing. Dedicated protocols based on an 
initial de-methylation step were recently developed to overcome this limitation, allowing for 
direct measurement of each tRNA abundance and detailed mapping of modifications [62,63]. 
While some methods focus exclusively on mature tRNAs [64], partial alkaline RNA hydrolysis 
complemented with tRNA precursors enrichment identified tRNA leaders, trailers, and introns 
and showed that around half of all predicted tRNA genes are transcribed in human cells [65]. 
While tRNA abundance is a major modulator of translational elongation, the aminoacylation 
state has to also be considered. The addition of chemical steps that specifically remove the 
3’A residue in uncharged tRNA coupled with the aforementioned de-methylation RNA-Seq 
protocols showed most cytosolic tRNAs in HEK293T cells are charged at >80% levels, whereas 
tRNASer and tRNAThr are charged at lower levels [66]. 
An additional layer of regulation during elongation is chemical modification of nucleotides 
among tRNAs [67]. One of the key enzymes to regulate the methylation state of tRNAs is the 
demethylase ALKBH1, which acts dynamically in response to specific conditions such as 
variations in glucose availability to impact translation at both the initiation and the elongation 
phases [68]. These modifications can have different effects depending on the target tRNA and 
the position in the transcript, as it was shown ALKBH1 is required for the formation of 
essential methylations at position 34 of anticodon in cytoplasmic tRNALeu and mitochondrial 
tRNAMet [69]. Advances in high-throughput sequencing and data analysis have also allowed 
the identification of new classes of small non-coding RNAs derived from tRNAs: stress-
induced tRNA halves (tiRs) and tRNA-related fragments (tRFs). These RNAs act on cell 
proliferation, priming of viral reverse transcriptase, regulation of gene expression, RNA 
processing, modulation of the DNA damage response, tumor suppression, and stress 
response [70]. The application of such approaches to study tRNAs in CHO cells will further 
elucidate the mechanism(s) by which tRNAs and their modifications modulate translation. 
FUTURE DIRECTIONS AND CHALLENGES 
Our understanding and ability to manipulate the translational machinery and harness non-
coding RNAs to enhance global and recombinant protein synthesis in CHO cells has advanced 
rapidly in the last decade. Further, the advent of the Chinese hamster and CHO cell line 
genomes has helped in the identification of non-coding RNAs such that these can be studied 
and manipulated. The ability of non-coding RNAs, in particular microRNAs, siRNAs, lncRNAs 
and tRNAs to tune both global and transcript specific translation, and hence protein synthesis, 
offers enormous opportunities to use these to enhance cell growth and proliferation, extend 
culture lifetimes, and increase recombinant protein yields and quality. However, our ability 
to harness these non-coding RNAs by engineering of CHO cells is currently limited by our 
knowledge of the mechanisms and targets by which many of these non-coding RNAs elicit 
their responses. The manipulation of microRNAs that can, in theory, tune multiple target 
transcripts appears an appealing approach, however in our view this approach alone is 
unlikely to deliver new commercially viable host cells with dramatically enhanced phenotypes 
due to the fact these are ‘tuning’ molecules and tend to be negative regulators and off target 
approaches can be difficult to control. Where these might be more applicable is for the tuning 
of transcript targets with a specific role, such as enzymes involved in glycosylation or to 
harness modulation of the cells own endogenous microRNA pool as inducible controllers of 
exogenous gene circuits. The potential of lncRNA engineering is very much in its infancy and 
would appear to offer the potential to act as negative and positive regulators of gene 
expression. The limitation here is that many of these are, as the name suggests, long RNAs 
and thus the manipulation is more challenging and we do not yet understand what, if any, 
role many of these play in the cell. The control of gene expression via the elongation step of 
mRNA translation and tRNA availability, charging and modification, linked with improved 
predictive models for how such changes in abundance or modification change elongation 
rates of target mRNAs is likely to offer advances that can be directly applied industrially to 
engineering of the target recombinant gene(s) and of pathways in the cell to deliver new 
engineered host cell lines with improved growth, productivity and post-translational 
modification abilities. However, the major challenge will be to unravel the mechanisms by 
which the control on gene expression that these different non-coding RNAs provide are 
coordinated together, in order to reprogram the translational efficiency of current CHO cell 
chassis, under appropriate bioprocessing conditions (including continuous processes) to 
generate new chassis with enhance bioprocessing properties. 
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Table 1. Summary of non-coding RNA cell engineering studies discussed in this review grouped by 
type of approach, with the reported experimental effect and the relative reference. 
Method Effect Reference 
siRNA LDH-A activities were decreased by 75-89%, while the specific glucose consumption rates 
reduced by 54-87% and the specific lactate production rates reduced to 45-79% of the 
control cell line level. 
[32] 
 
 siRNA mediated inhibition of PDHKs and LDH-A in CHO cells expressing a therapeutic 
monoclonal antibody reduced lactate production, increased specific productivity and 
volumetric antibody production by 90%, 75% and 68%, respectively. 
[33] 
 
 Ribosome profiling identified NeoR as a highly transcribed and translated gene in an IgG-
producing CHO cell line. Viable cell concnetration was increased by 35% upon siRNA knock-
down of NeoR, which was accompanied by an 18% increase in product titer. 
[34] 
 
 Combined transient siRNA-mediated knockdown of the expression of the endoplasmic 
reticulum localized proteins CerS2 and Tbc1D20 resulted in a 50-66% increase in specific 
productivity of CHO-IgG cells. 
[35] 
miRNA Co‐expression of miR‐557 and a difficult‐to‐express antibody resulted in a two-fold increase 
in product titer. 
[27] 
 miR-143 overexpression resulted in a 20% final increase in mAb productivity. [28] 
 Addition of a synthetic 3'UTR to destabilize DHFR expression allowed the generation of 
stable DG44-derived cell pools expressing a model monoclonal antibody (mAb) with low MTX 
concentrations. 
[29] 
 Inhibition of miR-124-3p and miR-19b-3p in CHO increased X-linked inhibitor of apoptosis 
protein levels, enhancing CHO cell growth and prolonged culture longevity while additionally 
boosting productivity. 
[31] 
lncRNA Engineering of CHO cells with SINEUP long non-coding RNAs resulted in a 150% increase in 
periostin levels in cell supernatant at 72 h post-transfection. 
[50] 
 The development of a 'universal' protein expression enhancer tool based upon long non-
coding RNAs gave expression enhancement in various mammalian cells of recombinant 




Modification of human interleukin-2 (IL-2) through codons with high gene copy number and 
high codon usage bias significantly increased protein productivity in CHO-K1 cells. 
[52] 
 Codon de-optimization of a bispecific antibody sequence through the introduction of less 
frequently occurring codons in CHO gave a 2-fold final yield increase. 
[55] 
 In vivo expression of various codon context (CC) optimized IFN-γ in CHO cells exhibited at least 
13-fold increase in expression compared to the wild-type IFN-γ while a maximum of 10-fold 
increase was observed for the individual codon usage (ICU) optimized genes.  
[60] 
 
 
